Get started
Author

Karim Belhadj‐Merzoug

Observed names: Belhadj-Merzoug, K., Belhadj-Merzoug, Karim, K. Belhadj-Merzoug, K. Belhadj‐Merzoug, Karim Belhadj-Merzoug
Observed institutions: Karolinska University Hospital, Karolinska Institutet, Centre Hospitalier Universitaire Henri-Mondor, Hôpital Cardiologique du Haut-Lévêque, Hôpitaux Universitaires Henri-Mondor, Hôpital Mustapha Pacha
OpenAlex ID: A5083707252
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
2022 · Thierry Facon, Gordon Cook, et al. · Leukemia · 129
PDF
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab
2021 · Joseph Mikhael, Karim Belhadj-Merzoug, et al. · Blood Cancer Journal · 88
PDF
Apixaban for the prevention of thromboembolism in immunomodulatory‐treated myeloma patients: Myelaxat, a phase 2 pilot study
2019 · Brigitte Pegourie, Lionel Karlin, et al. · American Journal of Hematology · 61
Venous thromboembolism prophylaxis and multiple myeloma patients in real-life: Results of a large survey and clinical guidance recommendations from the IFM group
2023 · Laurent Frenzel, Olivier Decaux, et al. · Thrombosis Research · 25
Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
2019 · Xavier Leleu, Guillemette Fouquet, et al. · Clinical Cancer Research · 15
Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIA
2019 · Pieter Sonneveld, Michel Attal, et al. · Clinical Lymphoma Myeloma & Leukemia · 11
Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03)
2015 · Xavier Leleu, Lionel Karlin, et al. · Blood · 10
The EMMY longitudinal, cohort study: real-world data to describe multiple myeloma management and outcomes as more therapeutic options emerge
2024 · Olivier Decaux, Ronan Garlantézec, et al. · Clinical Hematology International · 8
PDF
Improving Advanced-Line Multiple Myeloma Care: Insights and Real-World Challenges from the EMMY Study
2025 · Titouan Cazaubiel, Olivier Decaux, et al. · Clinical Hematology International · 4
PDF
Changes in Patterns of Hodgkin’s Disease in Algeria, 1966–1985: Influence of Health Care Delivery System
2009 · Pierre Colonna, Karim Belhadj-Merzoug, et al. · Acta Haematologica · 4
Hodgkin's disease, clinical stages IA to IIIB: Combined modality therapy (3 MOPP followed by curative and prophylactic radiotherapy including the spleen). Six‐year results
1987 · P. Colonna, J. M. Andrieu, et al. · European Journal Of Haematology · 4
Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03)
2017 · Xavier Leleu, Guillemette Fouquet, et al. · Clinical Lymphoma Myeloma & Leukemia · 3
Advanced Hodgkin disease (clinical stages IIIB and IV): Low relapse rate after brief chemotherapy followed by high‐dose total lymphoid irradiation
1989 · P. Colonna, J. M. Andrieu, et al. · American Journal of Hematology · 3
Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma
2021 · Arthur Bobin, Maéva Kyheng, et al. · Leukemia · 1
A Prospective Phase II Trial of Lenalidomide and Dexamethasone in POEMS Syndrome
2019 · Arnaud Jaccard, Lionel Karlin, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Supplementary Tables from Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
2023 · Xavier Leleu, Guillemette Fouquet, et al.
PDF
Supplementary Figures from Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
2023 · Xavier Leleu, Guillemette Fouquet, et al.
Supplementary Figures from Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
2023 · Xavier Leleu, Guillemette Fouquet, et al.
Data from Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
2023 · Xavier Leleu, Guillemette Fouquet, et al.
Data from Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
2023 · Xavier Leleu, Guillemette Fouquet, et al.
Supplementary Tables from Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial
2023 · Xavier Leleu, Guillemette Fouquet, et al.
Maintenance with Weekly Carfilzomib in Elderly newly Diagnosed Multiple Myeloma (IFM 2012-03).
2019 · Arthur Bobin, Guillemette Fouquet, et al. · Clinical Lymphoma Myeloma & Leukemia
Pf592 Impact of Age on Efficacy and Safety of Daratumumab in Combination With Lenalidomide and Dexamethasone (d-rd) in Patients With Transplant-ineligible Newly Diagnosed Multiple Myeloma (ndmm): Maia
2019 · C. Hulin, T. Facon, et al. · HemaSphere
Pf607 Maintenance With Weekly Carfilzomib in Elderly Newly Diagnosed Multiple Myeloma (ifm 2012–03)
2019 · A. Bobin, G. Fouquet, et al. · HemaSphere
IFM2012-03
2016 · Xavier Leleu, Guillemette Fouquet, et al. · Blood
Works count: 30
Citation count: 367
H-index: 8
I10-index: 7
Year
Topic
Type